Patients with fibrosing interstitial lung disease (ILD) who began supplemental oxygen therapy had triple the per patient per month ILD-related health care costs compared with those who did not.

Delayed diagnosis of fibrotic ILD leads to higher mortality rates and shorter overall survival, emphasizing the need for early clinical recognition. Supplemental oxygen therapy in fibrotic ILD ...